NCT07533006

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last approximately 48 weeks, including screening.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	LY4005130	Administered IV
DRUG	Placebo	Administered IV

Timeline

• Start date: 2026-04-14
• Primary completion: 2027-06-21
• Completion: 2027-10-10
• First posted: 2026-04-16
• Last updated: 2026-04-16

Locations

29 sites across 7 countries: United States, Canada, China, Netherlands, Poland, South Korea, United Kingdom

Regulatory

• FDA-regulated drug study